Original Publication Date: 1 October, 2014
Publication / Source: Hepatic Oncology
Authors: Geraldine O'Sullivan Coyne, Tim F Greten
The notable emergence of immunotherapy as an effective and durable anti-tumor treatment strategy is driving intense clinical research into new agents. The recent approval of the first anti-programmed death (PD)-1 antibody, pembrolizumab, by the US FDA in August 2014 for metastatic melanoma, has highlighted the increasingly dominant role that cancer immunotherapy agents play in the oncology therapeutic arsenal.